Oral Bioavailability of Bilastine

Healthy Clinical Trial

— BIOBI  

Official title:

Study to Assess Oral Bioavailability of Bilastine (Estudio de Biodisponibilidad Oral de Bilastina)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01124123
• Other study ID #: BILA 2909/BA
• Secondary ID: 2010-019049-25
• Status: Completed
• Phase: Phase 1
• First received: May 13, 2010
• Last updated: September 25, 2012
• Start date: May 2010
• Est. completion date: September 2010

Study information

• Verified date: September 2012
• Source: Faes Farma, S.A.
• Contact: n/a
• Is FDA regulated: No
• Health authority: Spain: Spanish Agency of Medicines
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess the absolute bioavailability of an oral bilastine formulation (test drug) compared to the endovenous administration of an IV bilastine formulation (control drug) in healthy volunteers.

Description:

Single centre, open label, cross-over, randomised, controlled, single dose study. The primary endpoint is the determination of plasma concentrations versus time (17 samples per subject at various time intervals after dosing) in order to assess the oral bioavailability of bilastine in healthy volunteers. Therefore the primary pharmacokinetic variable will be the area under the plasma concentration versus time curve from time zero to infinity (AUC 0-∞). Additionally the following pharmacokinetic variables will also be assessed: Cmax, AUC 0-t, tmax, Ae, Clr, t1/2. Additional objectives are to describe the safety and tolerability of a single administration of oral and endovenous bilastine in healthy volunteers.

Twelve healthy volunteers will be included. Each volunteer will take in random order one single dose of 20 mg oral bilastine and 10 mg IV bilastine with a minimum washout period of 14 days between them.

Bilastine plasma concentrations will be measured using a liquid chromatography/mass mass spectrometry (LC/MS/MS) micro method

Recruitment information / eligibility

• Status: Completed
• Enrollment: 12
• Est. completion date: September 2010
• Est. primary completion date: June 2010
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 35 Years

Eligibility

Inclusion Criteria:

• Healthy volunteers of either sex aged from = 18 to = 35 years of age.

• Body mass index between 19 and 29 Kg/m2.

• Non smokers.

• Judged to be in general good health based on medical history, physical examination and clinical laboratory tests.

• Able to communicate well with the investigator and to comply with the requirements of the entire study.

• Provision of written informed consent to participate.

Exclusion Criteria:

• Pregnant or breast-feeding women or with a positive pregnancy test. Subjects who do not agree to use an adequate method of contraception during the study.

• Intake of another investigational medication in another clinical study within 4 months prior to the first study drug intake.

• Regular use of any prescribed medication including medicinal herbs or OTC medication within 4 weeks of dosing.

• A QTc> 430 ms in males and a QTc> 450 ms in females. A HR <55 bpm.

• Existence of any surgical or medical condition which, in the judgement of the investigator, might interfere with the absorption, distribution, metabolism or excretion of the IMP.

• Known allergy/hypersensitivity to the study drug or its inactive ingredients.

• Any clinical conditions or circumstances that in the opinion of the investigator would make the subject unsuitable for the study (e.g., hepatic impairment, renal impairment, mental impairment, cardiac disease).

• Presence of hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV Ab) or HIV 1 or HIV 2 antibodies at screening.

• Subjects who have taken metabolic or transporter inducers/inhibitors during the 3 months prior to inclusion in the study.

• Donation or loss of greater than 200 mL of blood within 12 weeks before entry to the study.

• Blood transfusion within the prior 6 months to inclusion.

• Ingestion of citrus fruits and cranberries or any fruit juice within 7 days prior to first dose of study medication.

• Known current alcohol or drug abuse.

• Excessive consumption of xanthine containing foods or drinks.

• Mentally disabled subjects or subjects who by official order have been institutionalised must be excluded from participation.

Study Design

Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science

Related Conditions & MeSH terms

• Healthy

Intervention

Drug:
• Bilastine
20 mg oral tablet
• Bilastine
10 mg endovenous bilastine

Locations

Country	Name	City	State
Spain	Unidad de Investigacion Clinica. Clinica Universidad de Navarra	Pamplona	Navarra

Sponsors (1)

Lead Sponsor	Collaborator
Faes Farma, S.A.

Country where clinical trial is conducted

Spain, 

References & Publications (2)

Jauregizar N, de la Fuente L, Lucero ML, Sologuren A, Leal N, Rodríguez M. Pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effect of bilastine. Clin Pharmacokinet. 2009;48(8):543-54. doi: 10.2165/11317180-000000000-00000. — View Citation

Lucero ML, Gonzalo A, Ganza A, Leal N, Soengas I, Ioja E, Gedey S, Jahic M, Bednarczyk D. Interactions of bilastine, a new oral H1 antihistamine, with human transporter systems. Drug Chem Toxicol. 2012 Jun;35 Suppl 1:8-17. doi: 10.3109/01480545.2012.682653. Erratum in: Drug Chem Toxicol. 2012 Oct;35(4):472. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The area under the plasma concentration versus time curve from time zero to infinity (AUC 0-8 ).	Bilastine bioavailability will be obtained from the oral AUC 0-8 / endovenous AUC 0-8 quotient.	17 blood draws performed at: 0,25 - 0,5- 0,75 - 1 - 1,25 - 1,5 - 1,75 - 2 - 2,5 - 3 - 4 - 5 - 7 - 12 - 24 - 48 and 72 hours post administration.	No
Secondary	Additional pharmacokinetic variables: Cmax, AUC 0-t, tmax, Ae, CLr and t ½	Cmax: Maximum plasma concentration; the highest concentration observed during a dosage interval; tmax: The time that Cmax was observed; AUC 0-t: The area under the plasma concentration versus time curve from time zero to the last time point; Ae: amount of accumulated unaltered drug in urine till the last time point; Clr: Renal clearance; t ½: Elimination halflife	17 blood draws and urine collection during 72 hours post administration	No
Secondary	Safety and tolerability of a single dose administration of oral and endovenous bilastine	Safety will be assessed during the study by monitoring adverse events (AEs), clinical laboratory test results (urinalysis, blood chemistry, and haematology), vital signs (including blood pressure, respiration, temperature, and heart rate, supine and standing), electrocardiogram (ECG) results, and abnormal findings upon physical examination.	A last Follow up visit will be performed 7 days after last drug intake	Yes

External Links

•   Clinical Pharmacology Department. Clinica Universidad Navarra (CUN)
•   Clinical Trials and Medical Research page. Clinica Universidad Navarra (CUN)